Sanofi
- Country
- 🇫🇷France
- Ownership
- Public
- Employees
- 87.9K
- Market Cap
- $141.3B
- Website
- http://www.sanofi.com
- Introduction
Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.
DILIPO (DILutIonal HyPOnatremia)
- Conditions
- First Posted Date
- 2006-01-10
- Last Posted Date
- 2008-09-15
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 150
- Registration Number
- NCT00274326
- Locations
- 🇸🇪
Sanofi-Aventis Administrative Office, Bromma, Sweden
🇦🇺sanofi-aventis Australia & New Zealand administrative office, Macquarie Park, New South Wales, Australia
TELICAST : Telithromycin in Acute Exacerbations of Asthma
- Conditions
- First Posted Date
- 2006-01-09
- Last Posted Date
- 2009-09-15
- Lead Sponsor
- Sanofi
- Registration Number
- NCT00273520
Induction Chemotherapy Comparing Taxotere® Cisplatin and 5-Fluorouracil (TPF) With Standard Cisplatin and 5-Fluorouracil (PF) Followed by Chemoradiation in Locally Advanced Head and Neck Cancer
- Conditions
- First Posted Date
- 2006-01-09
- Last Posted Date
- 2009-04-29
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 500
- Registration Number
- NCT00273546
- Locations
- 🇷🇺
Sanofi-Aventis Administrative Office, Moscow, Russian Federation
EMINEM: Efficacy of Muscoril In NEck Myofascial Syndromes
- Conditions
- First Posted Date
- 2006-01-06
- Last Posted Date
- 2008-02-20
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 65
- Registration Number
- NCT00272532
- Locations
- 🇹🇷
Sanofi-Aventis, Istanbul, Turkey
Insulin Glargine in Type 2 Diabetes Mellitus
- Conditions
- First Posted Date
- 2006-01-04
- Last Posted Date
- 2009-12-07
- Lead Sponsor
- Sanofi
- Registration Number
- NCT00272077
XENOX - Evaluation of the Efficacy of Xaliproden in Reducing the Neurotoxicity of the Oxaliplatin + 5-FU/LV Chemotherapy
- Conditions
- First Posted Date
- 2006-01-04
- Last Posted Date
- 2006-09-13
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 620
- Registration Number
- NCT00272051
Insulin Glargine in Type 1 Diabetes Mellitus
- Conditions
- First Posted Date
- 2006-01-04
- Last Posted Date
- 2011-06-08
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 489
- Registration Number
- NCT00272090
ELEONOR STUDY: Insulin Glulisine in Type 2 Diabetes Mellitus.
- Conditions
- Interventions
- First Posted Date
- 2006-01-04
- Last Posted Date
- 2009-12-07
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 352
- Registration Number
- NCT00272064
- Locations
- 🇮🇹
Sanofi-Aventis Administrative Office, Milan, Italy
OPAL - Insulin Glulisine, Diabetes Mellitus
- Conditions
- First Posted Date
- 2006-01-04
- Last Posted Date
- 2009-12-07
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 396
- Registration Number
- NCT00272012
- Locations
- 🇩🇪
Sanofi-Aventis, Berlin, Germany
Safety Study of Sodium Divalproate in Bipolar Disorder in Adolescents
- Conditions
- First Posted Date
- 2005-12-30
- Last Posted Date
- 2011-01-11
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 200
- Registration Number
- NCT00271258
- Locations
- 🇫🇷
Sanofi-Aventis, Paris, France